WO2005049000A3 - Treatment of phenylketonurias with bh4 - Google Patents
Treatment of phenylketonurias with bh4 Download PDFInfo
- Publication number
- WO2005049000A3 WO2005049000A3 PCT/US2004/038296 US2004038296W WO2005049000A3 WO 2005049000 A3 WO2005049000 A3 WO 2005049000A3 US 2004038296 W US2004038296 W US 2004038296W WO 2005049000 A3 WO2005049000 A3 WO 2005049000A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- phenylketonurias
- treatment
- hyperphenylalaninemia
- contemplated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK04819152.2T DK1708690T3 (en) | 2003-11-17 | 2004-11-17 | TREATMENT OF PHENYLKETONURI WITH BH4 |
CA2545584A CA2545584C (en) | 2003-11-17 | 2004-11-17 | Methods and compositions for the treatment of metabolic disorders |
JP2006539992A JP2007511536A (en) | 2003-11-17 | 2004-11-17 | Methods and compositions for the treatment of metabolic disorders |
PL16178739T PL3138566T3 (en) | 2003-11-17 | 2004-11-17 | Treatment of phenylketonuria with bh4 |
BRPI0416566-7A BRPI0416566A (en) | 2003-11-17 | 2004-11-17 | phenylketonuria treatment with bh4 |
EP04819152.2A EP1708690B1 (en) | 2003-11-17 | 2004-11-17 | Treatment of phenylketonuria with bh4 |
EP21209606.9A EP3977999A1 (en) | 2003-11-17 | 2004-11-17 | Treatment of phenylketonuria with bh4 |
AU2004291149A AU2004291149C1 (en) | 2003-11-17 | 2004-11-17 | Methods and Compositions for the Treatment of Metabolic Disorders |
ES04819152.2T ES2596827T3 (en) | 2003-11-17 | 2004-11-17 | Treatment of phenylketonuria with BH4 |
MXPA06005451A MXPA06005451A (en) | 2003-11-17 | 2004-11-17 | Treatment of phenylketonurias with bh4. |
CN2004800338351A CN1905863B (en) | 2003-11-17 | 2004-11-17 | Methods and compositions for the treatment of metabolic disorders |
EP16178739.5A EP3138566B1 (en) | 2003-11-17 | 2004-11-17 | Treatment of phenylketonuria with bh4 |
IL175529A IL175529A (en) | 2003-11-17 | 2006-05-09 | Tetrahydrobiopterin (bh4) or optionally a salt form thereof for use in the treatment of a subject with phenylketonuria(pku) |
HK07102354.9A HK1094875A1 (en) | 2003-11-17 | 2007-03-02 | Treatment of phenylketonuria with bh4 bh4 |
CY20161101054T CY1118171T1 (en) | 2003-11-17 | 2016-10-19 | THERAPEUTIC TREATMENT OF BEN4 |
CY20221100068T CY1124931T1 (en) | 2003-11-17 | 2022-01-27 | TREATMENT OF PHENYL KETONOURIA WITH BH4 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52076703P | 2003-11-17 | 2003-11-17 | |
US60/520,767 | 2003-11-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005049000A2 WO2005049000A2 (en) | 2005-06-02 |
WO2005049000A3 true WO2005049000A3 (en) | 2005-11-10 |
Family
ID=34619513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/038296 WO2005049000A2 (en) | 2003-11-17 | 2004-11-17 | Treatment of phenylketonurias with bh4 |
Country Status (19)
Country | Link |
---|---|
US (6) | US7566714B2 (en) |
EP (3) | EP3977999A1 (en) |
JP (2) | JP2007511536A (en) |
KR (1) | KR20070005550A (en) |
CN (1) | CN1905863B (en) |
AU (1) | AU2004291149C1 (en) |
BR (1) | BRPI0416566A (en) |
CA (1) | CA2545584C (en) |
CY (2) | CY1118171T1 (en) |
DK (2) | DK1708690T3 (en) |
ES (2) | ES2905305T4 (en) |
HK (1) | HK1094875A1 (en) |
HU (2) | HUE029533T2 (en) |
IL (1) | IL175529A (en) |
MX (1) | MXPA06005451A (en) |
PL (2) | PL1708690T3 (en) |
PT (2) | PT1708690T (en) |
SI (1) | SI3138566T1 (en) |
WO (1) | WO2005049000A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1708690T3 (en) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Treatment of phenylketonuria with bh4 |
WO2006055511A2 (en) * | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
WO2007072911A1 (en) * | 2005-12-22 | 2007-06-28 | Asubio Pharma Co., Ltd. | Preparation with improved bioabsorbability of sapropterin hydrochloride |
WO2007119367A1 (en) * | 2006-03-20 | 2007-10-25 | Kaneka Corporation | Composition containing biopterin and method for using the same |
CA2675134A1 (en) * | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Pterin analogs |
LT2545939T (en) | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels |
US20080275726A1 (en) * | 2007-05-02 | 2008-11-06 | Steven Yannicelli | System and method for metabolic patient management and treatment |
CA2711160A1 (en) | 2008-01-03 | 2009-07-16 | Biomarin Pharmaceutical Inc. | Pterin analog for treating bh4 responsive condition |
BRPI0907247A2 (en) * | 2008-01-07 | 2015-07-14 | Biomarin Pharm Inc | Methods for preparing biopterin and for preparing tetrahydrobiopterin |
UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
ES2669094T3 (en) * | 2009-06-12 | 2018-05-24 | Wisconsin Alumni Research Foundation | Medicinal foods of glycomapropeptides for the nutritional treatment of phenylketonuria and other metabolic disorders |
IT1399244B1 (en) * | 2009-07-31 | 2013-04-11 | Pharmarte S R L | FORMULATION OF BARRIER SPECIFIC FOR PREGNANCY. |
EP2601946A1 (en) * | 2011-12-06 | 2013-06-12 | Pécsi Tudomànyegyetem | Treatment and prevention of diseases related to oxidative stress |
WO2014018873A2 (en) | 2012-07-27 | 2014-01-30 | Chemic Laboratories Inc. | Compositions comprising folic acid derivatives. their preparations and methods of use |
EP2918683A4 (en) * | 2012-11-09 | 2016-06-01 | Sanyo Foods Co Ltd | Protein complex capable of catalyzing asymmetric oxidation reaction and method for producing same |
CA2972638C (en) | 2015-01-09 | 2023-11-28 | Mcmaster University | Allosteric activators for treatment of phenylketonuria, and method for identifying allosteric activators |
US20180221371A1 (en) * | 2015-08-07 | 2018-08-09 | Children's National Medical Center | Treatment for the fetus with congenital heart disease |
JP2019527242A (en) | 2016-07-29 | 2019-09-26 | ディファーマ エッセ.ア. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
CN110312721A (en) * | 2016-11-29 | 2019-10-08 | 显莎制药公司 | The polymorph of sepiapterin |
BR122021026889A8 (en) * | 2016-11-29 | 2022-11-22 | Censa Pharmaceuticals Inc | FREE BASE CRYSTALLINE FORMS OF SEPIAPTERIN AND SALTS THEREOF, THEIR METHOD OF PREPARATION, COMPOSITIONS THAT COMPRISE THEM, USE OF THEM AND METHOD OF PREPARATION OF A LIQUID FORMULATION |
JP2020532535A (en) | 2017-09-01 | 2020-11-12 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | Pharmaceutical composition containing sepiapterin and its use |
IT201700099690A1 (en) * | 2017-09-06 | 2019-03-06 | Abiogen Pharma Spa | COMPOSITION FOR SOCCER INTEGRATION |
CN107751998A (en) * | 2017-09-29 | 2018-03-06 | 赤峰禾士营养食品科技有限公司 | A kind of edible formula powder for phenylketonuria patient |
AU2019277382A1 (en) | 2018-05-30 | 2021-01-21 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
CN113727733B (en) * | 2019-02-14 | 2023-01-24 | 索姆创新生物技术公司 | Triamterene or nolatrexed for treating phenylketonuria |
TR201914416A1 (en) * | 2019-09-23 | 2021-04-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Effervescent formulations of sapropterin dihydrochloride |
CN112362785B (en) * | 2020-11-19 | 2022-12-27 | 南京工业大学 | Application of a group of diagnostic markers in diagnosis of asthenospermia caused by varicocele |
CN114569607B (en) * | 2022-02-28 | 2024-02-13 | 军事科学院军事医学研究院环境医学与作业医学研究所 | Application of 5-hydroxytryptophan in preparation of health care product or medicine for improving female physiological cycle disorder caused by altitude hypoxia |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252822A (en) * | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
EP0108890A2 (en) * | 1982-09-20 | 1984-05-23 | The Wellcome Foundation Limited | Pharmaceutically active pteridine derivatives |
US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
US4713454A (en) * | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
EP0488078A1 (en) * | 1990-11-24 | 1992-06-03 | MILUPA GmbH & Co. KG | Diet free of phenylalanin for juveniles and adults affected with phenylketonurea |
JPH059065B2 (en) * | 1982-10-29 | 1993-02-03 | Suntory Ltd | |
EP1314782A1 (en) * | 2000-08-31 | 2003-05-28 | Suntory Limited | Process for producing biopterins |
WO2004058268A2 (en) * | 2002-12-20 | 2004-07-15 | Orphanetics Pharma Entwicklungs Gmbh | Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders |
WO2005049614A2 (en) * | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
WO2005065018A2 (en) * | 2003-11-17 | 2005-07-21 | Merck Eprova Ag | Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride |
Family Cites Families (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US810A (en) | 1838-06-27 | Amokyamsden | ||
US452822A (en) * | 1891-05-26 | Cultivator and seed-planter | ||
US5902A (en) | 1848-11-07 | Universal instrument-sharpener | ||
US2603643A (en) | 1947-03-13 | 1952-07-15 | Hoffmann La Roche | 2-amino-4-hydroxy-6-polyhydroxyalkyl pteridine and methods of oxidizing same |
US2601215A (en) | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
US2541717A (en) | 1948-10-18 | 1951-02-13 | Upjohn Co | Pterine imines |
US2568685A (en) | 1950-07-22 | 1951-09-18 | Upjohn Co | 2-amino-4-hydroxy-6-omega-carboxytrihydroxy-propylpteridines |
US2955110A (en) | 1955-01-13 | 1960-10-04 | American Cyanamid Co | Substituted pteridines and method of preparing the same |
US3505329A (en) | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
JPS5399971A (en) | 1977-02-12 | 1978-08-31 | Nec Corp | Satellite posture detecting system |
GB2056459B (en) | 1979-07-04 | 1983-03-09 | Daiichi Radioisotope Lab | Pterin derivatives and an assay method for determining pterins |
JPS5883691A (en) | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | 1',2'-diacyl-(6r,s)-5,6,7,8-tetrahydro-l-biopterin and its preparation |
JPS5925323A (en) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | Depression disease parkinsonism therapy made from pterin derivative |
JPS5921685A (en) | 1982-07-28 | 1984-02-03 | Suntory Ltd | Preparation of tetrahydro-l-biopterin |
GB8318833D0 (en) | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
ZA836957B (en) | 1982-09-20 | 1985-04-24 | Wellcome Found | Neurologically active chemical compounds |
JPS6011581Y2 (en) | 1982-11-12 | 1985-04-17 | 古河電気工業株式会社 | Receptacle for printed circuit board |
JPS5982091U (en) | 1982-11-26 | 1984-06-02 | 株式会社バンダイ | Traveling toy with suction cup |
US5196533A (en) | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
US4587340A (en) | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
JPS60178887A (en) * | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | Preparation of 5,6,7,8-tetrahydro-l-biopterin |
JPS60199889A (en) | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8-tetrahydro-l-erythro-biopterin sulfate and its preparation |
JPS60204786A (en) | 1984-03-29 | 1985-10-16 | Univ Nagoya | Synthesis of (6r)-tetrahydrobiopterin and its relating substance |
DE3437944A1 (en) | 1984-10-17 | 1986-07-31 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | USE OF PTERINES TO INCREASE THE ACTIVITY OF LYMPHOKINES AND OTHER BLOOD FACTORS, AND A DIAGNOSTIC OR THERAPEUTIC PREPARATION CONTAINING PTERINE IN COMBINATION WITH LYMPHOKINES |
JPS61277618A (en) | 1985-06-04 | 1986-12-08 | Suntory Ltd | Remedy for autism |
US4707361A (en) | 1985-08-02 | 1987-11-17 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
JPH0692302B2 (en) | 1986-09-02 | 1994-11-16 | 鐘淵化学工業株式会社 | Neurological agent |
EP0278040B1 (en) | 1987-02-13 | 1991-08-14 | Pharm-Allergan Gmbh | Use of pteridines and/or purines or of a xanthineoxidase inhibitor for the preparation of a medicament for the treatment of hereditary degenerative retinal diseases |
CA1334654C (en) | 1987-11-30 | 1995-03-07 | Masayasu Kurono | Intermediates for synthesizing bh _and its derivatives |
EP0349204A3 (en) | 1988-06-28 | 1991-08-07 | Bend Research, Inc. | Use and regeneration of reagents using coupled reactions and permselective barriers |
GB8823804D0 (en) * | 1988-10-11 | 1988-11-16 | Holgates Nutritional Foods Ltd | Proteinaceous composition |
JP2843592B2 (en) | 1989-02-28 | 1999-01-06 | 日清製粉株式会社 | L-ribose derivative |
US5006344A (en) | 1989-07-10 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Fosinopril tablet formulations |
US5554647A (en) | 1989-10-12 | 1996-09-10 | Perricone; Nicholas V. | Method and compositions for treatment and/or prevention of skin damage and aging |
WO1991012814A1 (en) | 1990-02-28 | 1991-09-05 | E.I. Du Pont De Nemours And Company | Activation of monocyte/macrophages |
JPH04210624A (en) | 1990-12-11 | 1992-07-31 | Shigenobu Sakata | Bathing agent and lotion having medicinal effect |
US5194469A (en) * | 1991-02-28 | 1993-03-16 | The Goodyear Tire & Rubber Company | Latex for coatings having improved flexibility |
CZ227093A3 (en) | 1991-04-29 | 1994-03-16 | Merck & Co Inc | Mixture suitable for the preparation of tablets by direct moulding |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
WO1993010155A1 (en) | 1991-11-16 | 1993-05-27 | Suntory Limited | 6(r)-l-erythro-5,6,7,8-tetrahydrobiopterin receptor |
JP2534423B2 (en) | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | Inhibitors that prevent vascular disorders resulting from overproduction of nitric oxide |
US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
DE4215275A1 (en) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Means and methods for the treatment of body fluids in the determination of neopterin |
US6251953B1 (en) | 1992-10-30 | 2001-06-26 | Andrew Brookner | Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein |
US5830461A (en) | 1992-11-25 | 1998-11-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods for promoting wound healing and treating transplant-associated vasculopathy |
US20020061862A1 (en) | 1992-11-25 | 2002-05-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase for treatment of disease |
CA2150125A1 (en) | 1992-11-25 | 1994-06-09 | Timothy R. Billiar | Cdna clone for human inducible nitric oxide synthase and process for preparing same |
US5658565A (en) | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
US5468772A (en) | 1993-03-10 | 1995-11-21 | Pharmagenesis, Inc. | Tripterinin compound and method |
WO1994021275A1 (en) | 1993-03-19 | 1994-09-29 | Vacsyn S.A. | Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine |
DE4308739C1 (en) | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterin derivatives, their preparation and their use |
US5449688A (en) | 1993-03-30 | 1995-09-12 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating chronic inflammatory diseases |
CH686369A5 (en) | 1994-05-09 | 1996-03-15 | Eprova Ag | Stable crystalline (6S) - and (6R) -Tetrahydrofolseure. |
US5945452A (en) | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
WO1995013075A1 (en) | 1993-11-12 | 1995-05-18 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
TW282398B (en) | 1993-12-22 | 1996-08-01 | Bristol Myers Squibb Co | |
WO1995028377A1 (en) | 1994-04-18 | 1995-10-26 | Abbott Laboratories | Guanidine compounds as regulators of nitric oxide synthase |
DE4418096A1 (en) | 1994-05-24 | 1995-11-30 | Cassella Ag | Use of pteridine derivatives as inhibitors of NO synthase |
US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
EP0722731B1 (en) | 1994-08-05 | 2002-06-05 | Suntory Limited | Remedy for spinocerebellar degeneration |
US5643586A (en) | 1995-04-27 | 1997-07-01 | Perricone; Nicholas V. | Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds |
US5799283A (en) * | 1995-05-10 | 1998-08-25 | Francisco; Paul A. | Point of sale governmental sales and use tax reporting and receipt system |
US5744340A (en) | 1995-06-09 | 1998-04-28 | Schering Corporation | Expression of human inducible nitric oxide synthase |
SE506533C2 (en) | 1995-07-03 | 1998-01-12 | Birger Andersson | A process for in vitro analysis of the toxic and allergenic properties of substances and the use of neopterin to distinguish between allergic immune reactions |
CA2228970A1 (en) * | 1995-08-18 | 1997-02-27 | Donald W. Landry | Detection of organic compounds through regulation of antibody-catalyzed reactions |
US5879690A (en) | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
DE19534602C2 (en) * | 1995-09-18 | 1999-09-09 | Milupa Ag | Use of threonine to treat phenylketonuria |
US5811437A (en) | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
JP2711828B2 (en) | 1996-06-25 | 1998-02-10 | 白鳥製薬株式会社 | Method for producing (6R) -tetrahydro-L-biopterin hydrochloride |
US5856158A (en) | 1996-07-05 | 1999-01-05 | University Of Iowa Research Foundation | Purified nitric oxide synthase from rat brain |
US20020076782A1 (en) | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
DE69733308D1 (en) | 1996-07-31 | 2005-06-23 | Cmic Co | ACTIVE SULFUR-CONTAINING PTERID DERIVATIVES |
GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
DE69725721T3 (en) | 1996-08-30 | 2007-10-31 | Daiichi Asubio Pharma Co., Ltd. | PREVENTIVE OR HEALING MEDICINE FOR DISEASES CAUSED BY LACK OF STAIN OXIDE SYNTHASE (NOS) |
WO1998008402A1 (en) * | 1996-08-30 | 1998-03-05 | Societe Des Produits Nestle S.A. | Nutritional formula for phenylketonuria patients |
WO1998028298A1 (en) | 1996-12-24 | 1998-07-02 | Research Development Foundation | Ricin inhibitors and methods for use thereof |
US6562969B1 (en) | 1996-12-24 | 2003-05-13 | Research Development Foundation | Ricin inhibitors and methods for use thereof |
US6428990B1 (en) | 1997-04-11 | 2002-08-06 | Abbott Laboratories | Human desaturase gene and uses thereof |
US5846775A (en) | 1997-04-22 | 1998-12-08 | Incyte Pharmaceuticals, Inc. | GTP cyclohydrolase I regulatory protein |
CH693255A5 (en) | 1997-06-13 | 2003-05-15 | Eprova Ag | Use of tetrahydrofolates natürlichenstereoisomeren in the form suitable for the preparation of a pharmaceutical composition for influencing the homocysteine level. |
US5922713A (en) | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
AU1189399A (en) | 1997-10-15 | 1999-05-03 | Uab Research Foundation | Bathocuproine treatment of neurologic disease |
ES2242381T3 (en) | 1998-02-27 | 2005-11-01 | Daiichi Suntory Pharma Co., Ltd. | PROPHLACTIC AGENTS OR REMEDIES AGAINST RENAL DISORDERS OF MEDICINAL ORIGIN. |
JP4306825B2 (en) | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | Preventive or therapeutic agent for diseases associated with vascular dysfunction involving insulin resistance |
US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
US6162914A (en) | 1998-04-24 | 2000-12-19 | Cerbios-Pharma S.A. | Process for the reduction of pterins |
US6117872A (en) | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
US6423751B1 (en) | 1998-07-14 | 2002-07-23 | The Brigham And Women's Hospital, Inc. | Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
WO2000003746A2 (en) | 1998-07-14 | 2000-01-27 | The Brigham And Women's Hospital, Inc. | Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
US6346519B1 (en) * | 1998-09-09 | 2002-02-12 | Advanced Medical Instruments | Method and composition for treating arthritis |
US6656925B2 (en) | 1998-09-09 | 2003-12-02 | Advanced Medical Instruments | Composition and method of treating arthritis |
AU2380800A (en) | 1998-12-22 | 2000-07-12 | Board Of Regents, The University Of Texas System | Structural basis for pterin function in nitric oxide synthase |
US7276506B2 (en) * | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
US6319905B1 (en) | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
CA2361936C (en) | 1999-01-08 | 2009-06-16 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
US6200758B1 (en) | 1999-02-19 | 2001-03-13 | New York State Office Of Mental Health | Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
JP2003511347A (en) | 1999-03-19 | 2003-03-25 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | Upregulation of type III endothelial cell nitric oxide synthase by HMG-CoA reductase inhibitor |
EP1175210A4 (en) | 1999-03-19 | 2003-07-09 | Enos Pharmaceuticals Inc | Increasing cerebral bioavailability of drugs |
CH693905A5 (en) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stable crystalline salts of 5-methyl tetrahydrofolic acid. |
US6288535B1 (en) | 1999-07-06 | 2001-09-11 | Jacob Chass | Hall effect, shaft angular position sensor with asymmetrical rotor |
ATE408406T1 (en) | 1999-07-28 | 2008-10-15 | Univ Leland Stanford Junior | USE OF NICOTINE IN ANGIOGENESIS AND VASCULOGENesis |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
US20020155445A1 (en) | 1999-12-16 | 2002-10-24 | Jarvik Jonathan W. | Methods and products for peptide based DNA sequence identification and analysis |
SE0000307D0 (en) | 2000-01-31 | 2000-01-31 | Univ Zuerich | Method and formulation for treatment of vasoconstriction |
EA006181B1 (en) | 2000-02-29 | 2005-10-27 | Бристоль-Мейерз Сквибб Компани | Based on entecavir pharmaceutical composition and method of preparing thereof |
AUPQ598300A0 (en) | 2000-03-03 | 2000-03-23 | Citrus Sensation Pty Ltd | Citrus fruit preservative |
US6576105B1 (en) | 2000-03-31 | 2003-06-10 | Truman State University | Pteridine analysis by capillary electrophoresis using laser-induced fluorescence detection |
WO2001078717A1 (en) | 2000-04-12 | 2001-10-25 | Cornell Research Foundation, Inc. | Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity |
US6544994B2 (en) | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
WO2002000933A2 (en) * | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
AU2001284865A1 (en) * | 2000-08-14 | 2002-02-25 | Joan M. Fallon | Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
WO2002017898A2 (en) | 2000-09-01 | 2002-03-07 | Sacks Meir S | Compositions and methods for inducing vasorelaxation |
DE10043845A1 (en) * | 2000-09-06 | 2002-03-14 | Gruenenthal Gmbh | Method of measuring NO synthase activity |
DE10047455A1 (en) | 2000-09-26 | 2002-04-11 | Hilti Ag | Screwing device for a strip-shaped screw magazine |
US6689385B2 (en) | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
WO2002042292A2 (en) * | 2000-11-20 | 2002-05-30 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
UA80393C2 (en) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix |
US6537992B2 (en) | 2001-01-05 | 2003-03-25 | John D. Parker | Regulation of organic nitrate tolerance |
TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
US6693094B2 (en) | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
US6500857B1 (en) | 2001-08-16 | 2002-12-31 | Nicholas V. Perricone | Subcutaneous muscle treatment using electronic stimulation and topical compositions |
US20030004125A1 (en) | 2001-06-22 | 2003-01-02 | Hirst David G. | Inducible gene |
US20030078231A1 (en) * | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
US20030153972A1 (en) | 2002-02-14 | 2003-08-14 | Michael Helmus | Biodegradable implantable or insertable medical devices with controlled change of physical properties leading to biomechanical compatibility |
CH696628A5 (en) | 2002-02-26 | 2007-08-31 | Eprova Ag | Use of folate suitable for the manufacture of a preparation for the prevention and treatment of inflammation and inflammation-associated diseases, in particular for influencing the |
AU2002357798A1 (en) | 2002-03-11 | 2003-09-29 | Boyce Thompson Institute For Plant Research | Plant nitric oxide synthase |
JP4836388B2 (en) * | 2002-03-22 | 2011-12-14 | 第一三共株式会社 | Preventive or therapeutic agent for diseases caused by eNOS expression |
US7465555B2 (en) | 2002-04-02 | 2008-12-16 | Becton, Dickinson And Company | Early detection of sepsis |
US20040037809A1 (en) | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
WO2004016764A2 (en) | 2002-08-16 | 2004-02-26 | Schering Aktiengesellschaft | eNOS MUTANTS USEFUL FOR GENE THERAPY |
DE60236025D1 (en) | 2002-08-22 | 2010-05-27 | Vasopharm Biotech Gmbh | PHARMACEUTICAL COMPOSITION CONTAINING L-ARGININE |
US6953799B1 (en) | 2002-10-30 | 2005-10-11 | Bach Pharma, Inc. | Modulation of cell fates and activities by diketo phthalazines |
NL1021892C2 (en) | 2002-11-11 | 2004-05-12 | Tno | Detection of demyelination. |
PL1708690T3 (en) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Treatment of phenylketonuria with bh4 |
DK1757293T3 (en) | 2004-05-11 | 2012-10-22 | Daiichi Sankyo Co Ltd | BH4-RESPONSIVE HYPERPHENYLALANINARY MEDICINES |
EP1768653A4 (en) * | 2004-06-25 | 2012-08-01 | Univ Texas | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
EP1814984A2 (en) | 2004-09-17 | 2007-08-08 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
US20060088566A1 (en) | 2004-10-27 | 2006-04-27 | Scimed Life Systems, Inc.,A Corporation | Method of controlling drug release from a coated medical device through the use of nucleating agents |
WO2006055511A2 (en) | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
US20060194808A1 (en) * | 2005-01-14 | 2006-08-31 | Chronorx Llc, An Alaska Limited Liability Company | Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate |
FR2888499B1 (en) | 2005-07-13 | 2008-01-04 | Oreal | METHOD OF MAKE-UP AND / OR COSMETIC CARE |
LT2545939T (en) | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels |
-
2004
- 2004-11-17 PL PL04819152T patent/PL1708690T3/en unknown
- 2004-11-17 CA CA2545584A patent/CA2545584C/en active Active
- 2004-11-17 WO PCT/US2004/038296 patent/WO2005049000A2/en active Application Filing
- 2004-11-17 DK DK04819152.2T patent/DK1708690T3/en active
- 2004-11-17 EP EP21209606.9A patent/EP3977999A1/en not_active Withdrawn
- 2004-11-17 HU HUE04819152A patent/HUE029533T2/en unknown
- 2004-11-17 PT PT48191522T patent/PT1708690T/en unknown
- 2004-11-17 ES ES16178739T patent/ES2905305T4/en active Active
- 2004-11-17 AU AU2004291149A patent/AU2004291149C1/en active Active
- 2004-11-17 HU HUE16178739A patent/HUE058126T2/en unknown
- 2004-11-17 SI SI200432516T patent/SI3138566T1/en unknown
- 2004-11-17 DK DK16178739.5T patent/DK3138566T3/en active
- 2004-11-17 MX MXPA06005451A patent/MXPA06005451A/en active IP Right Grant
- 2004-11-17 ES ES04819152.2T patent/ES2596827T3/en active Active
- 2004-11-17 EP EP04819152.2A patent/EP1708690B1/en not_active Revoked
- 2004-11-17 KR KR1020067012001A patent/KR20070005550A/en not_active Application Discontinuation
- 2004-11-17 EP EP16178739.5A patent/EP3138566B1/en active Active
- 2004-11-17 JP JP2006539992A patent/JP2007511536A/en active Pending
- 2004-11-17 BR BRPI0416566-7A patent/BRPI0416566A/en not_active Application Discontinuation
- 2004-11-17 PT PT161787395T patent/PT3138566T/en unknown
- 2004-11-17 PL PL16178739T patent/PL3138566T3/en unknown
- 2004-11-17 CN CN2004800338351A patent/CN1905863B/en not_active Ceased
-
2005
- 2005-06-01 US US11/143,887 patent/US7566714B2/en active Active
-
2006
- 2006-05-09 IL IL175529A patent/IL175529A/en active IP Right Grant
- 2006-10-02 US US11/542,310 patent/US20080090832A1/en not_active Abandoned
-
2007
- 2007-03-02 HK HK07102354.9A patent/HK1094875A1/en not_active IP Right Cessation
-
2009
- 2009-07-23 US US12/508,209 patent/US8067416B2/en active Active
-
2011
- 2011-11-16 US US13/297,644 patent/US9433624B2/en active Active
-
2012
- 2012-06-28 JP JP2012145046A patent/JP2012207029A/en active Pending
-
2016
- 2016-09-02 US US15/255,467 patent/US9993481B2/en active Active
- 2016-10-19 CY CY20161101054T patent/CY1118171T1/en unknown
-
2018
- 2018-05-08 US US15/973,986 patent/US20180256582A1/en not_active Abandoned
-
2022
- 2022-01-27 CY CY20221100068T patent/CY1124931T1/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252822A (en) * | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
EP0108890A2 (en) * | 1982-09-20 | 1984-05-23 | The Wellcome Foundation Limited | Pharmaceutically active pteridine derivatives |
JPH059065B2 (en) * | 1982-10-29 | 1993-02-03 | Suntory Ltd | |
US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
US4713454A (en) * | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
EP0488078A1 (en) * | 1990-11-24 | 1992-06-03 | MILUPA GmbH & Co. KG | Diet free of phenylalanin for juveniles and adults affected with phenylketonurea |
EP1314782A1 (en) * | 2000-08-31 | 2003-05-28 | Suntory Limited | Process for producing biopterins |
WO2004058268A2 (en) * | 2002-12-20 | 2004-07-15 | Orphanetics Pharma Entwicklungs Gmbh | Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders |
WO2005049614A2 (en) * | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
WO2005065018A2 (en) * | 2003-11-17 | 2005-07-21 | Merck Eprova Ag | Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride |
Non-Patent Citations (5)
Title |
---|
CERONE R ET AL: "Long-term follow-up of a patient with mild tetrahydrobiopterin-respo nsive phenylketonuria", MOLECULAR GENETICS AND METABOLISM 2004 UNITED STATES, vol. 81, no. 2, 2004, pages 137 - 139, XP002344606, ISSN: 1096-7192 * |
DATABASE WPI Section Ch Week 199308, Derwent World Patents Index; Class B02, AN 1984-155421, XP002345070 * |
SEASHORE M R: "Tetrahydrobiopterin and dietary restriction in mild phenylketonuria", NEW ENGLAND JOURNAL OF MEDICINE 26 DEC 2002 UNITED STATES, vol. 347, no. 26, 26 December 2002 (2002-12-26), pages 2094 - 2095, XP009053409, ISSN: 0028-4793 * |
STEINFELD R ET AL: "A hypothesis on the biochemical mechanism of BH4-responsiveness in phenylalanine hydroxylase deficiency", AMINO ACIDS 2003 AUSTRIA, vol. 25, no. 1, March 2003 (2003-03-01), pages 63 - 68, XP002345063, ISSN: 0939-4451 * |
TREFZ F K ET AL: "Potential Role of Tetrahydrobiopterin in the Treatment of Maternal Phenylketonuria", PEDIATRICS 2003 UNITED STATES, vol. 112, no. 6 II, 2003, pages 1566 - 1569, XP009053410, ISSN: 0031-4005 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005049000A3 (en) | Treatment of phenylketonurias with bh4 | |
WO2006063215A3 (en) | Methods and compositions for the treatment of pulmonary hypertension of the newborn | |
TW200604168A (en) | Azaindoles useful as inhibitors of rock and other protein kinases | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
MX349188B (en) | Sns-595 and methods of using the same. | |
WO2005037323A3 (en) | Use of gro to treat or prevent inflammation | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
WO2006068729A3 (en) | Methods and compositions for enhancing iron absorption | |
MXPA06001134A (en) | INHIBITORS OF Akt ACTIVITY. | |
WO2005097119A3 (en) | Pten inhibitors | |
WO2006030439A3 (en) | Compositions and methods for inducing hair growth | |
WO2005105780A3 (en) | Compositions useful as inhibitors of rock and other protein kinases | |
HK1113569A1 (en) | Pyrazolo | |
EP1190099A4 (en) | Antisense modulation of pi3k p85 expression | |
WO2005013901A3 (en) | Oligomeric compounds and compositions for use in modulation of small non-coding rnas | |
PT1420801E (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
IL164509A0 (en) | Furyl compounds | |
WO2004011610A3 (en) | Antisense modulation of polo-like kinase expression | |
WO2005004808A3 (en) | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | |
WO2007130501A3 (en) | Combination therapy for treatment of cancer | |
WO2004004653A3 (en) | Methods for treating psychosis associated with interferon-alpha therapy | |
WO2006078336A3 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
WO2005062958A3 (en) | Meth0ds of using hcn genes to treat cardiac arrhythmias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480033835.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 175529 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004291149 Country of ref document: AU Ref document number: 2545584 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2668/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/005451 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006539992 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2004291149 Country of ref document: AU Date of ref document: 20041117 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004291149 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2004819152 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004819152 Country of ref document: EP Ref document number: 1020067012001 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004819152 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067012001 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0416566 Country of ref document: BR |